Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd. et al.

I'll research this case to verify the details before drafting.

Let me gather more details on the patents, IPRs, and procedural history.

Let me verify the appellate counsel, IPR activity, and market context.

Case Overview and Background

The parties. The plaintiffs are the co-owners of the patents-in-suit: Helsinn Healthcare S.A., a privately held, family-run Swiss pharmaceutical company headquartered in Lugano-Pazzallo that in-licenses and develops drug candidates (a "business-to-business" model — it had no U.S. sales force and no internal formulation labs at the relevant time), and Roche Palo Alto LLC, the Delaware entity (formerly Syntex (U.S.A.) Inc., at One DNA Way, South San Francisco) that discovered palonosetron and ran its early Phase I/II trials before licensing the program to Helsinn in 1998. Both are operating life-sciences companies, not NPEs. The defendants are all generic drug manufacturers that filed ANDAs with Paragraph IV certifications: [Dr. Reddy's Laboratories, Ltd.](/litigations/by-plaintiff/Dr.%20Reddy's%20Laboratories%2C%20Ltd.) (India) and Dr. Reddy's Laboratories, Inc. (its New Jersey subsidiary); Sandoz, Inc. (the Novartis generics unit, at the time with a Princeton, NJ office); and Teva Pharmaceuticals USA, Inc. with parent Teva Pharmaceutical Industries, Ltd. (Israel). Per the complaint (Dkt. 1, filed 07/08/2011), the case arose under the Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)(A), based on each defendant's ANDA — for Teva, ANDA No. 090713 covering generic palonosetron hydrochloride intravenous solutions at 0.25 mg/5 mL (for chemotherapy-induced nausea and vomiting, "CINV") and 0.075 mg/1.5 mL (for post-operative nausea and vomiting, "PONV"). The reference product is Helsinn's brand Aloxi®, which was marketed in the United States by Eisai; Aloxi is a selective 5-HT₃ receptor antagonist IV antiemetic. (I could not independently verify specific Aloxi U.S. revenue figures, so I omit them rather than guess.)

The patents and technology. The four asserted patents cover stable, ready-to-use IV palonosetron formulations rather than the palonosetron molecule itself (the compound was claimed in Roche's earlier U.S. Patent No. 5,202,333, which Helsinn licensed). The district court framed the asserted claims as the '724 patent claims 2 and 9, the '725 patent claim 2, the '424 patent claim 6, and the '219 patent claims 1, 2, and 6 (the supplemental opinion lists claims 1, 2, 6, and 7 of the '219). The '724, '725, and '424 patents are pre-AIA and share a common technical core: a pharmaceutically stable isotonic aqueous palonosetron solution, with palonosetron at about 0.05 mg/mL (equivalent to a 0.25 mg dose given as 5 mL), buffered to an acidic pH (e.g., 4.0–6.0 or 4.5–5.5), containing EDTA as a chelant/stabilizer and typically mannitol as a tonicifier. The '219 patent is post-AIA (filed May 2013, claiming priority to a January 30, 2003 provisional) and claims an express fixed dose of 0.25 mg palonosetron in a 5 mL solution with EDTA and mannitol, stable for 24 months at room temperature — a difference in claim format that mattered because only the '219 patent was governed by the AIA's § 102(a)(1). Because all four asserted claims cover the same 0.25 mg dose, the Federal Circuit treated them together in the appeal.

Procedural posture and venue. The lead case is No. 3:11-cv-03962 (MLC)(DEA) in the U.S. District Court for the District of New Jersey, Trenton vicinage (Clarkson S. Fisher U.S. Courthouse), before Judge Mary L. Cooper and Magistrate Judge Douglas E. Arpert. It was consolidated with Civ. Nos. 11-5579 and 13-5815 (and related to No. 12-2867 against Hospira). Sandoz was dismissed by consent on December 31, 2014; Dr. Reddy's was dismissed on stipulation on October 16, 2015, leaving Teva as the sole trial defendant. After an 11-day bench trial in June 2015 and closing arguments on August 12, 2015, Judge Cooper issued a memorandum opinion on November 13, 2015 and final judgment for Helsinn on November 16, 2015, followed by a supplemental opinion on March 3, 2016, 2016 WL 832089. The court held the asserted claims valid and infringed (except that Teva's 0.075 mg/1.5 mL PONV product did not infringe the '219 patent), rejecting Teva's obviousness, written-description, and on-sale-bar defenses. Teva appealed on November 30, 2015 (Fed. Cir. No. 16-1284), and the Federal Circuit reversed on May 1, 2017, holding the asserted claims invalid under the on-sale bar — Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) (Dyk, J., with Mayer and O'Malley). The Supreme Court granted certiorari and affirmed in a unanimous opinion by Justice Thomas on January 22, 2019, Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 586 U.S. ___, 139 S. Ct. 628 (2019). Venue was significant here: New Jersey is a hub for Hatch-Waxman litigation and for these defendants' U.S. operations, and Judge Cooper's court in particular handled a cluster of Aloxi-related ANDA suits, as reflected in its April 5, 2016 personal-jurisdiction ruling allowing Helsinn's parallel claims against Hospira to proceed in the district based on ANDA-related contacts and the state's interest in the consolidated litigation.

Why it matters. The case is principally a precedent-setting on-sale-bar case, not a typical NPE assertion. The invalidity turned on agreements Helsinn executed with MGI Pharma in April 2001 — roughly two years before the January 30, 2003 priority date — under which MGI received U.S. distribution/supply rights to 0.25 mg and 0.75 mg palonosetron. The agreements were publicly announced and filed (partially redacted) in MGI's SEC Form 8-K, but the specific dosage formulations were not disclosed and were subject to confidentiality. A split panel question emerged: the district court held there was no qualifying sale under the AIA absent public disclosure of the invention, while the Federal Circuit held that "if the existence of the sale is public, the details of the invention need not be publicly disclosed." The Supreme Court resolved it by holding that the AIA's added catchall "or otherwise available to the public" did not narrow the settled pre-AIA meaning of "on sale," so a confidential "secret sale" to a third party can invalidate a patent. The practical consequences were two-fold: (1) it invalidated Helsinn's Aloxi formulation patents and cleared the way for generic palonosetron competition; and (2) it ran counter to then-current USPTO examination practice (the Patent Office had been treating post-AIA secret sales as non-qualifying art), prompting examination-practice adjustment and a wave of commentary, with the case now standard authority cited in Federal Circuit and district court on-sale and § 102(a)(1) disputes. On the IPR linkage: the four patents-in-suit went to judgment without a PTAB inter partes review of those claims; the related PTAB activity in this family involved later-generation Helsinn patents (e.g., DRL's PGR2016-00007 on U.S. Patent No. 9,173,942 and an IPR on U.S. Patent No. 8,729,094, which were asserted in the Hospira action), and later Helsinn patents have since been challenged in PTAB proceedings by other petitioners — so I would not characterize this specific case as an IPR-driven outcome. Appellate counsel included Kannon K. Shanmugam (Williams & Connolly) for Helsinn at the Supreme Court, supported by Paul Hastings (Joseph M. O'Malley, Jr. and Eric W. Dittmann) and Saul Ewing (Charles M. Lizza), against William M. Jay (Goodwin Procter) and Winston & Strawn (Steffen N. Johnson, Andrew C. Nichols) for Teva — all drawn from the Supreme Court opinion's caption and the oral-argument transcript in No. 17-1229 (argued December 4, 2018).

Note on sourcing: party identities, the asserted claims, dismissal dates, and the docket history above are drawn from the complaint (Dkt. 1), Judge Cooper's November 13, 2015 memorandum opinion (Dkt. 360) and March 2016 supplemental opinion (2016 WL 832089), the Federal Circuit opinion at 855 F.3d 1356, and the Supreme Court opinion at 139 S. Ct. 628, with the docket sequence (Sandoz dismissal Dkt. 247; DRL dismissal Dkt. 355; appeal notice Dkt. 365) from the CourtListener/PACER docket for 3:11-cv-03962. Where I have flagged uncertainty (e.g., Aloxi revenue, the precise scope of PTAB challenges to these four patents), I was unable to confirm it from the sources retrieved and have not asserted it.

I'll research this case thoroughly across the docket, opinions, PTAB, and press coverage.

Let me dig into the district court opinion, the Federal Circuit decisions, and any PTAB proceedings.

Let me get the docket-level detail and the PTAB proceedings on the '219 patent.

I'll search for press coverage across the case angles: the Supreme Court and Federal Circuit rulings, the district court trial, and the industry roundups listed.

Let me verify the two "known" articles and find the original Reuters/other legacy coverage.

Press coverage

The trial win (November 2015). Reuters Legal reported on 2015‑11‑17 that Judge Cooper's ruling meant "Teva Pharmaceutical Industries Ltd cannot launch a version of Helsinn Healthcare SA's antinausea drug Aloxi in the U.S. until the latter's patent protection expires in 2024." Pharmaceutical Business Review reported on 2015‑11‑18 the more granular figure — that "the term of the formulation patent rights and pediatric exclusivity currently provides coverage for Aloxi through to 30 July 2024" — and paired it with the earlier settlements: Dr. Reddy's and Sandoz "will [not] be allowed to launch a generic version of palonosetron hydrochloride through an ANDA before 30 September 2018, except under several circumstances." Helsinn's co-promotion partner Eisai issued a same-day release (No. 15‑77) confirming the validity/infringement judgment and the same 2024 expiry and 2018 settlement dates. The most-quoted commercial datapoint traces to Helsinn's own outside counsel: the Reuters story on the 2017 reversal (Jan Wolfe; Reuters, reprinted by KIIP) stated that "Lugano, Switzerland‑based Helsinn generates about 90 percent of its annual revenue from Aloxi, according to a press release from Helsinn's outside law firm Paul Hastings."

The Federal Circuit reversal (May 2017). Reuters' Wolfe reported that the May 1 decision "invalidated Helsinn Healthcare SA's patents on its anti‑nausea treatment Aloxi, clearing the way for Teva Pharmaceuticals Industries Ltd. to launch a generic version of the drug," and framed the holding as answering "a novel legal question" — that "the on‑sale bar is triggered by a publicly announced sale even if the details of the patented invention are not disclosed." BioCentury (2017‑06‑02) identified the four patents by number and described the ruling as allowing "competition from a generic palonosetron product from Teva." The Pharma Letter (2017‑05‑02) and Pharmaceutical Technology both stressed the launch was not immediate — that Teva "will not be able to launch a generic version of Aloxi until additional steps are taken by the Federal Circuit, the New Jersey Court and the Food and Drug Administration" — a caveat several trade outlets took verbatim from Helsinn's press release. IPWatchdog treated the decision as the Federal Circuit's first interpretation of the AIA on‑sale bar.

Certiorari and the Supreme Court decision (2018–2019). IPWatchdog covered the cert grant (2018‑06‑26), the 2018‑12‑04 oral argument (highlighting Justice Alito's colloquy with Teva's counsel on the "or otherwise available to the public" language), and the 2019‑01‑22 decision, quoting Justice Thomas's conclusion that the catch‑all phrase was "simply not enough of a change… to conclude that Congress intended to alter the meaning of the reenacted term 'on sale.'" IPWatchdog also ran a reaction roundup, "Opinions Mixed in Aftermath of Supreme Court Holding in Helsinn," canvassing views "from 'well‑reasoned and correct' to 'a disappointment' and 'dismissive'"; Venable publicized partner Chris Loh's contribution to it, in which he argued the ruling "puts patentees who depend on third‑party distributors at a disadvantage relative to patentees who have the ability to distribute their patented products in‑house." Practitioner analysis emphasized the mismatch with agency practice: Ropes & Gray (2019‑01‑24) headlined its alert "…in Counter to Current USPTO Procedure," noting the PTO had taken the position that the AIA "does not cover secret sales," and that then‑Rep. Lamar Smith (AIA co‑sponsor) had sided with Helsinn. Wilson Sonsini (2019‑01‑22) and Jones Day (January 2020 white paper) framed it as a drafting warning — file before any commercial agreement, confidential or not. Harvard JOLT noted the decision "does not assess the facts surrounding the transaction," i.e., it resolved only the statutory question.

Where accounts diverge or reach past the record. The numbers are the softest part of the coverage. The widely repeated "~90% of revenue from Aloxi" figure originates in a Paul Hastings press release, not in any court finding, and Reuters attributes it as such. Helsinn's trial counsel Saul Ewing's bio for Charles M. Lizza claims "market value of judgments $3.2 billion" and Aloxi "annual sales totaling more than $600 million" — advocacy figures from a law‑firm marketing page, and its description of a "12‑day bench trial" and "167‑page opinion" differs from the docket record reflected in the case background (11‑day trial; separate November 2015 opinion plus the March 2016 supplemental opinion). The two sides' characterizations of the 2001 MGI transaction also diverge in the press: Reuters described Helsinn as having "paid a drugmaker called MGI Pharma Inc. to produce batches of the drug for testing," whereas the opinions describe a license plus exclusive supply‑and‑purchase arrangement for FDA‑approved product. Corporate statements went beyond the rulings — Eisai (2018‑01‑18) said Helsinn and Eisai were "disappointed" after en banc rehearing was denied and asserted that "[a]dditional patents covering the product exist, which were not included in the Federal Circuit's prior decision," while also confirming Teva still could not launch pending further steps. Finally, a PTAB tracking chart published by Oblon lists PGR2014‑00010, filed 2014‑09‑02 by Accord Healthcare against U.S. Patent No. 8,598,219 with Roche Palo Alto LLC as patent owner. That appears to cut against the earlier section's statement that no PTAB review touched these claims — it was a post‑grant review rather than an IPR, and I could not retrieve the institution decision or outcome from the snippet, so I flag it as a discrepancy requiring confirmation rather than a settled correction.

On the two indexed articles. I attempted to verify both and could not confirm that either discusses this litigation: the GlobeNewswire item is a market‑research release on the global highly‑potent‑API sector and the Yahoo Entertainment item is a generic‑pharma partnering deal compendium covering 2014–2020; neither is, on its face, case coverage, and my searches returned no text tying either to Helsinn. I therefore do not cite them as reporting on the case. Substantive press coverage of this litigation clusters instead around three dates — November 2015, May 2017, and January 2019 — and is dominated by legal‑trade and law‑firm analysis rather than general‑assignment reporting; I found no Law360, Bloomberg Law, or Ars Technica piece I could verify by URL, so I have not cited any.

Sources

• January 24, 2019
• MARCH/APRIL 2019
• Supreme Court Affirms that Secret Sales Are Still Prior Art, Can Bar Patenting, in Counter to Current USPTO Procedure | Insights | Ropes & Gray LLP - - Home
• Helsinn Healthcare S. A. v. Teva Pharmaceuticals USA: Supreme Court Rules Secret Sales Could Bar Patent Eligibility Under the America Invents Act - Helsinn Healthcare S. A. v. Teva Pharmaceuticals USA: Supreme Court Rules Secret Sales Could Bar Patent Eligibility Under the Am...
• No
• 해외사법소식
• WILSON SONSINI
• U.S. SUPREME COURT UPHOLDS FEDERAL CIRCUIT RULING ON "SECRET SALES"
• Goodmans Update
• IP Blitz
• PRELIMINARY PRINT
• HELSINN HEALTHCARE S.A. V. TEVA PHARMS. USA, INC.:

I'll research the plaintiff-side counsel of record in this case, drawing on docket records, firm websites, and court opinions.

I have strong primary-source leads. Let me verify individual counsel details, roles, and any additional plaintiff-side attorneys.

Plaintiff-Side Counsel of Record — Helsinn Healthcare S.A. & Roche Palo Alto LLC

This section builds on the case background already drafted (which covered the appellate team — Shanmugam/Williams & Connolly at the Supreme Court; Paul Hastings and Saul Ewing on the merits appeal). Here I focus on the district-court trial team of record in No. 3:11-cv-03962 (and the consolidated/related D.N.J. actions).

Key structural point on "of record" vs. "of counsel." Because this was a D.N.J. case, the filings followed the district's local-counsel convention: the Saul Ewing LLP attorneys signed the pleadings as "Attorneys for Plaintiffs" of record, while the out-of-state Paul Hastings LLP team (for Helsinn) and Loeb & Loeb LLP (for Roche Palo Alto) appeared in the signature blocks under the heading "Of Counsel." Paul Hastings and Loeb & Loeb attorneys were admitted pro hac vice and actually tried the case (Dittmann is addressed directly by the court in the trial transcript). This dual structure is consistently reflected across the 2011 complaint, the 2014–2016 stipulations, and the Federal Circuit withdrawal papers.

Helsinn Healthcare S.A. (lead plaintiff)

Local counsel of record — Saul Ewing LLP (Newark, NJ; One Riverfront Plaza, Suite 1520)

• Charles M. Lizza — Lead local counsel / first-chair D.N.J. counsel. Signed the original complaint (Dkt. 1, filed 07/08/2011) and nearly every subsequent filing; argued before Judge Cooper and Magistrate Judge Arpert; also handled the Federal Circuit and the 2018 Supreme Court stay-of-mandate application. His firm bio credits him with representing Helsinn and Roche in the two Aloxi bench-trial wins (Teva and Dr. Reddy's) and describes him as "extremely knowledgeable about pharmaceutical patent litigation in the District of New Jersey."
• William C. Baton — Local counsel of record. Co-signed the complaint and the great majority of pleadings alongside Lizza.
• Sarah A. Sullivan — Associate/local counsel. Appears on the June 1, 2015 "pharmaceutically stable" claim-construction stipulation.

Of counsel / trial team — Paul Hastings LLP (New York, NY; 75 East 55th St. / 200 Park Ave.)

• Joseph M. O'Malley, Jr. — Lead trial counsel for Helsinn. Paul Hastings' Helsinn relationship partner; named by Reuters Legal as counsel of record in its November 17, 2015 trial-win report and named an NLJ "Intellectual Property Trailblazer" for his Helsinn work. Deep Hatch-Waxman trial résumé (Sunovion/Lunesta; Merck/Emend; Eisai/Aciphex and Aricept).
• Eric W. Dittmann — Trial counsel; PTAB lead counsel. Argued at trial (see the bench-trial transcript excerpt where the court addresses "Mr. Dittmann") and was lead counsel in the related IPRs on U.S. Pat. No. 8,729,094 (IPR2015-01550/01551/01553/01554).
• Bruce M. Wexler — Trial counsel. Paul Hastings IP partner; frequently co-lead trial counsel with O'Malley (e.g., Merck/Emend).
• David M. Conca — Trial counsel (named on the 2011 complaint).
• Gary Ji — Trial counsel (named on the complaint and later filings).
• Angela C. Ni — Trial counsel (appears 2011–2015).
• Isaac S. Ashkenazi — Trial counsel (appears 2015–2016).
• James R. Bliss — Trial counsel (June 2015 stipulation).
• Jason T. Christiansen — Trial counsel (late-2015 stipulation; filed a notice of appearance on behalf of Helsinn per the CourtListener docket).
• Young J. Park and Dana Weir — Trial counsel (2015–2016 signature blocks).

PTAB-only back-up (not district-court counsel): Thomas L. Irving (then Finnegan, Washington, D.C.), Reg. No. 28,619 — back-up counsel of record for Helsinn/Roche in the '094 IPRs.

Roche Palo Alto LLC (co-plaintiff; dismissed/withdrawn in 2016)

• Mark E. Waddell — Counsel for Roche Palo Alto LLC (and registered patent attorney, Reg. No. 31,803). Loeb & Loeb LLP, New York, NY; 345 Park Avenue. Signed pleadings consistently as "Attorneys for Plaintiff Roche Palo Alto LLC" from the 2011 complaint through the 2016 filings; when Roche assigned its rights to Helsinn and moved to withdraw from the Federal Circuit appeal (Fed. Cir. No. 16-1284, filed 05/16/2016), Waddell and Lizza filed the unopposed motion to withdraw. Roche was formally dismissed from the companion 15-8663 action by stipulated order entered July 2016.

Notes, gaps, and caveats

• Relationship between the two firms. Saul Ewing signed as counsel for both Helsinn and Roche jointly (the standard D.N.J. caption "Attorneys for Plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC"), with Paul Hastings appearing of counsel for Helsinn alone and Loeb & Loeb for Roche alone. That allocation is visible verbatim in the 2011 complaint and the June 2015 stipulation.
• No in-house counsel of record. I found no Helsinn or Roche in-house attorney appearing on the district-court docket; all appearances trace to Saul Ewing, Paul Hastings, or Loeb & Loeb.
• Later-generation cases. The same plaintiff-side lineup (Saul Ewing's Lizza/Baton + Paul Hastings' O'Malley/Dittmann) recurs in the related Aloxi actions cited in the PTAB mandatory notices (e.g., 11-5579, 13-5815, 14-4274/6341, 12-2867, and the Actavis/Sagent/Fresenius/Hospira suits). Those are related dockets, not this consolidated case, and I list them only to show continuity of counsel.
• Unverified item I did not assert. One docket transcript snippet in the CourtListener record references a "Sheila R. … Duane Morris LLP" appearance. I could not confirm which party (or which case) that entry belongs to, so I have excluded it rather than guess at a role.
• Sourcing. Names and roles are drawn from the original complaint (Dkt. 1, 07/08/2011), the June 1, 2015 stipulation (construction of "pharmaceutically stable"), the PTAB Patent Owners' Mandatory Notices / Powers of Attorney in IPR2015-01550 & -01554, the Federal Circuit unopposed motion to withdraw (16-1284, Dkt. 110, 05/16/2016), the 2018 Supreme Court stay-of-mandate application, CourtListener/PACER docket entries (including notice of appearance by Jason T. Christiansen), the Paul Hastings firm bio for Joseph O'Malley, the Saul Ewing bio for Charles M. Lizza, and Reuters Legal's Nov. 17, 2015 report. I did not independently verify the bar-admission dates or current employment status of every supporting attorney; several of the named associates may since have changed firms.

I'll research the defense-side counsel of record for this consolidated Hatch-Waxman action.

Good initial leads. Let me dig into the specific counsel for each defendant group, including Sandoz.

Now let me pin down Sandoz's counsel and verify the DRL/Teva teams.

Counsel of Record — Defendants (Consolidated Case No. 3:11-cv-03962 (MLC)(DEA))

Sourcing note up front. This listing is reconstructed from the docket and case documents rather than from a single counsel-of-record register. The most reliable snapshots are: the June 15, 2015 trial transcript appearances (Dkt. 339), the June 19, 2014 Winston & Strawn filing (Dkt. 176), the Budd Larner signature block on Dkt. 174, the Sept. 7, 2012 proceeding minutes (Dkt. 101), the Federal Circuit Rule 47.4 counsel statement in Teva's corrected appellant brief (No. 16-1284, filed 03/07/2016), and the CourtListener docket for case 4310416. The case ran 2011–2016 across three consolidated actions (11-3962, 11-5579, 13-5815), and Sandoz exited by consent on 12/31/2014 (Dkt. 247) and DRL by stipulation on 10/16/2015 (Dkt. 355), so the roster changed over time. Where I could not confirm a firm affiliation from a retrieved filing, I say so rather than guess.

---

1. Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. (DRL)

Local / trial counsel — BUDD LARNER, P.C., 150 John F. Kennedy Parkway, Short Hills, NJ 07078.